You are here

Oyster Point Pharma

Viatris to buy two eye drug developers in deals worth up to $750M

BioPharma Dive

Mon, 11/7/22 - 05:29 pm

Oyster Point Pharma

Famy Life Sciences

Oyster Point plows ahead with 50 layoffs to focus on approved eye drug

Fierce Biotech

Fri, 08/12/22 - 10:26 am

Oyster Point Pharma

dry eye disease

Oyster Point Laying Off 50 with Focus on Dry Eye Drug Launch

BioSpace

Thu, 06/30/22 - 11:05 am

Oyster Point Pharma

dry eye disease

Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix

Motley Fool

Sat, 10/30/21 - 10:50 pm

dry eye disease

Oyster Point Pharma

FDA OKs an inhaled version of smoking cessation drug Chantix — for a common eye disease

Endpoints

Mon, 10/18/21 - 11:57 am

Oyster Point Pharma

dry eye disease

Oyster Point Pharma Inks Deal with Ji Xing for Dry Eye Disease Therapies

BioSpace

Sun, 08/8/21 - 12:00 am

Oyster Point Pharma

Ji Xing Pharmaceuticals

dry eye disease

Five Collaborations Unlocking Faster Drug Development this Week

BioSpace

Thu, 06/10/21 - 11:12 am

drug development

pulmonary fibrosis

Oyster Point Pharma

Adaptive Phage Therapeutics

clinical trials

Shoreline Biosciences

Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray

Endpoints

Mon, 05/11/20 - 10:36 am

Oyster Point Pharma

dry eye disease

The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Yahoo/Benzinga

Sun, 10/27/19 - 10:55 pm

Adamis Pharmaceuticals

Redhill Biopharma

Amag Pharmaceuticals

Agile Therapeutics

Agios Pharmaceuticals

Mirati Therapeutics

Sutro BioPharma

Bristol-Myers Squibb

Oyster Point Pharma

Oyster Point Pharma Files for $85 Million IPO

CP Wire

Mon, 10/7/19 - 10:57 am

Oyster Point Pharma

dry eye disease

Oyster Point Pharma Files for $85 Million IPO

Mon, 10/7/19 - 10:09 am

Oyster Point Pharma

dry eye disease